BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors [0.03%]
布鲁顿氏酪氨酸激酶抑制剂BIBW-2992治疗实体瘤研究进展
Natalie Minkovsky,Alan Berezov
Natalie Minkovsky
The anilino-quinazoline derivative BIBW-2992, which is being developed by Boehringer Ingelheim Corp for the potential treatment of solid tumors, is an oral dual receptor tyrosine kinase inhibitor of human EGF receptor (EGFR) and human epide...
Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy [0.03%]
Pazopanib——一种血管内皮生长因子受体酪氨酸激酶抑制剂癌症治疗药物
Barry Sloan,Noah S Scheinfeld
Barry Sloan
Pazopanib, which is being developed by GlaxoSmithKline plc, is an oral, second-generation multi-targeted tyrosine kinase inhibitor that targets VEGFR, platelet-derived growth factor receptor and c-kit, key proteins responsible for tumor gro...
Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances [0.03%]
从最近的进展中学到的非病毒载体递送siRNA的经验教训
Shyh-Dar Li,Leaf Huang
Shyh-Dar Li
siRNA is a potential therapeutic candidate for treating genetic and acquired diseases, including cancer, that cannot be easily cured by conventional drugs. The limiting step for siRNA-based therapy is the delivery of the oligonucleotide int...
Robert M Sharkey,David M Goldenberg
Robert M Sharkey
As interest in targeted therapies for cancer increases, radionuclides stand out not only for their ability to be detected by external scintigraphy, but also for their therapeutic capacity. Radionuclides need to be directed to the invading c...
Therapeutic prostate cancer vaccines: a review of the latest developments [0.03%]
治疗性前列腺癌疫苗：最新研究进展评述
Mahsa Mohebtash,Ravi A Madan,James L Gulley et al.
Mahsa Mohebtash et al.
Therapeutic cancer vaccines are well-tolerated immunotherapy modalities designed to activate the immune system to kill cancer cells without a significant effect on healthy cells. An improved understanding of tumor immunology has led to impr...
Antonio Mp Omuro
Antonio Mp Omuro
Molecularly targeted therapies hold the promise of providing new anticancer treatments that are more effective and less toxic than traditional cytotoxic chemotherapy. Unfortunately, results of first generation targeted therapy trials for ma...
Christopher P Leamon
Christopher P Leamon
Increasing evidence suggests that the folate receptor (FR) can be exploited for therapeutic applications. This endocytosing protein is well known to functionally mediate the cellular uptake of natural folates, various antifolates, and folat...
Michelle Arkin,Mark M Moasser
Michelle Arkin
Inactivation of the human epidermal growth factor receptor-2 (HER-2) tyrosine kinase holds significant promise as a cancer treatment hypothesis, making it a high-value target for drug discovery. Screening and structure-based efforts have le...
Not just nuclear proteins: 'novel' autophagy cancer treatment targets - p53 and HMGB1 [0.03%]
不只是核蛋白：“新型” 自噬抗癌治疗靶标-p53和HMGB1
Kristen M Livesey,Daolin Tang,Herbert J Zeh et al.
Kristen M Livesey et al.
Talarozole, a selective inhibitor of P450-mediated all-trans retinoic acid for the treatment of psoriasis and acne [0.03%]
用于治疗银屑病和痤疮的选择性P450介导的全反式维甲酸抑制剂塔拉罗唑
Aanand N Geria,Noah S Scheinfeld
Aanand N Geria
Talarozole, being developed by Barrier Therapeutics Inc under license from Johnson & Johnson, is a potent and selective inhibitor of cytochrome P450 26-mediated breakdown of endogenous all-trans retinoic acid for the treatment of psoriasis ...